Inhibitors of leucine rich repeat kinase 2

A compound of Formula (I)

• or a pharmaceutically acceptable salt thereof, wherein
• X is CH or N;
• n is 2, 3, 4 or 5;
• A is O or NRa, wherein
• Ra is
• H;
• C1-4alkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl, wherein C1-3alkoxyl is optionally substituted with one to three halo substituents;
• C3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl;
• or
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, and the heterocyclyl ring is optionally substituted with one to three substituents independently selected from halo and C1-3alkyl, which C1-3alky is optionally substituted with one to three halo substituents;
• R1 is
• 1) H, halo, CN;
• 2) C1-4alkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl, which C1-3alkoxyl is optionally substituted with one to three halo substituents;
• 3) C2-6alkenyl optionally substituted with one to three halo or C1-3alkyl, which C1-3alkyl is optionally substituted with one to three halo substituents;
• 4) C2-6alkynyl optionally substituted with one to three C1-3alkyl substituents, which C1-3alkyl is optionally substituted with one to three halo substituents;
• 5) C1-4alkoxyl optionally substituted with one to three halo substituents;
• 6) C3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkoxyl and C1-3alkyl, wherein C1-3alkoxyl and C1-3alkyl are optionally substituted with one to three halo substituents;
• 7) —OC3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkoxyl and C1-3alkyl;
• 8) four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, and the heterocyclyl ring is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkoxyl and C1-3alkyl;
• 9) —O-heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, wherein the heterocyclyl ring is a four to seven-membered ring optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkoxyl and C1-3alkyl;
• or
• 10) —SC1-4alkyl optionally substituted with one to three halo substituents;
• R2 is
• H, halo, CN;
• C1-4alkoxyl optionally substituted with one to three halo substituents;
• C1-4alkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl, which C1-3alkoxyl is optionally substituted with one to three halo substituents;
• or
• C3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl;
• R3 is
• 1) H;
• 2) —CO—Z, wherein Z is selected from the group consisting of
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N;
• C3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkyl, and C1-3alkoxyl;
• and
• C1-6alkyl optionally substituted with one to three substituents independently selected from halo and C1-3alkoxyl;
• 3) four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, and the heterocyclyl ring is optionally substituted with one to three substituents independently selected from the group consisting of
• halo;
• cyano;
• C1-3alkyl optionally substituted with one to three substituents independently selected from halo, hydroxyl and C1-3alkoxyl;
• C1-3alkoxyl optionally substituted with one to three substituents independently selected from halo, hydroxyl and C1-3alkoxyl;
• and
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, and the heterocyclyl ring is optionally substituted with one to three substituents independently selected from the group consisting of halo, C1-3alkyl and C1-3alkoxyl;
• 4) C1-6alkyl optionally substituted with one to three substituents independently selected from the group consisting of
• CN, hydroxyl, halo;
• C1-4alkoxyl optionally substituted with one to three substituents independently selected from halo, hydroxyl and C1-3 alkoxyl;
• —CO-Q, wherein Q is C1-4alkoxyl, hydroxyl or NRcRd, wherein Rc and Rd are each independently H or C1-4alkyl;
• and
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, wherein the heterocyclyl ring is optionally substituted with one to three halo substituents;
• 5) C3-7cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of
• halo, hydroxyl;
• C1-3alkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl;
• C1-4alkoxyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-3alkoxyl;
• and
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, wherein the heterocyclyl ring is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3 alkyl, and C1-3 alkoxyl;
• 6) C-linked 7-9 membered bridged cyclyl ring optionally having one or two heteroatom ring members independently selected from O and N, optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkyl and C1-3alkoxyl;
• 7) C-linked 7-10 membered spirane cyclyl ring optionally having one or two heteroatom ring members independently selected from O and N, optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkyl and C1-3alkoxyl;
• or
• 8) C-linked 6-9 membered fused cyclyl ring optionally having one or two heteroatom ring members independently selected from O and N, optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkyl and C1-3alkoxyl;
• R4 and R5, at each occurrence, are each independently selected from the group consisting of
• H, halo, hydroxyl;
• C1-4alkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, C1-4alkoxy, OC1-4haloalkyl, and four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N;
• C3-6cycloalkyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-4 alkoxyl;
• four to seven-membered heterocyclyl ring having one or two heteroatom ring members independently selected from O and N, wherein the heterocyclyl ring is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl, C1-3alkyl, and C1-3alkoxyl;
• and
• C1-4alkoxyl optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxyl and C1-4alkoxyl.